Last Updated : April 29, 2024
Details
| Call for patient/clinician input open | April 21, 2023 |
|---|---|
| Call for patient/clinician input closed | June 19, 2023 |
| Clarification: - Patient input submission received from Canadian Cancer Survivor Network | |
| Submission received | June 14, 2023 |
| Submission accepted | June 28, 2023 |
| Review initiated | June 29, 2023 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | September 14, 2023 |
| Deadline for sponsors comments | September 25, 2023 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | October 27, 2023 |
| Expert committee meeting (initial) | November 08, 2023 |
| Clarification: Recommendation deferred to December 6, 2023 pERC meeting due to additional clarification needed by committee | |
| Draft recommendation issued to sponsor | December 18, 2023 |
| Draft recommendation posted for stakeholder feedback | January 04, 2024 |
| End of feedback period | January 18, 2024 |
| Final recommendation issued to sponsor and drug plans | February 01, 2024 |
| Final recommendation posted | February 20, 2024 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 15, 2024 |
| Canada's Drug Agency review report(s) posted | April 29, 2024 |